Table 3.
Potential beneficial measures for addressing GV
Subjects | Measures | Results | References |
---|---|---|---|
Patients with type 1 diabetes | CGM | Reduced GV and improved protection against hypoglycemia | [87–89] |
Insulin analogues degludec | Minimized morning GV | [91] | |
Canagliflozin | Improved indices of GV | [92] | |
Dapagliflozin over 24 weeks | Improved GV without increasing the time spent in the range indicating hypoglycemia | [93] | |
Empagliflozin as adjunct to insulin | Decreased glucose exposure and variability and increased time in glucose target range | [103] | |
Combination of basal insulin with ipragliflozin or dapagliflozin | Improved TIR and the mean glucose level | [104] | |
Low carbohydrate diet | Resulted in more time in euglycemia, less time in hypoglycemia | [108–110] | |
Patients with type 2 diabetes | Dapagliflozin on 24-h | Improved measures of GV | [94] |
Once-weekly trelagliptin and once-daily alogliptin | Improved glycemic control and reduced GV without inducing hypoglycemia | [95] | |
Combination of basal insulin with a GLP-1 RA | Lowered GV and hypoglycemia | [96] | |
Exenatide once weekly | Improved daily glucose control and reduced GV | [97] | |
Lixisenatide added to basal insulin | Reduced GV and PPG excursions without increasing the risk of hypoglycemia | [98] | |
Liraglutide | Lower mean time in hyperglycemia | [99] | |
Combination of metformin and gemigliptin or sitagliptin | Significantly reduced GV | [100] | |
Vildagliptin or pioglitazone | Significantly reduced MAGE, glycated hemoglobin and mean plasma glucose levels | [101] | |
Combination of metformin and vildagliptin or glimepiride | Improved glucose level with a significantly greater reduction in GV and hypoglycemia | [102] | |
Intensive insulin therapy combined with metformin | Reduced both glucose fluctuation and nocturnal hypoglycemic risk | [105] | |
Low-carbohydrate high-fat diet | Reduced glycemic fluctuation | [106, 107, 111] | |
Sequence of food ingestion | Associated with lower post-lunch glucose excursions and lower glucose coefficients of variation | [115] | |
Aerobic and combined exercise sessions | Reduced glucose levels and GV | [116–118] | |
Short-term exercise training | Improved glycemic control and GV but unaffected oxidative stress | [119, 121] | |
Frequent interruptions of prolonged sitting | Improved fasting glucose and night-time glycemic variability | [120] | |
Others | Low glycemic index foods | Reduced the glycemic response and variability and promoted fat oxidation. | [112, 113] |
Food order | Reduced glycemic excursions | [114] | |
Exercise in the fasted and postprandial state | Exercise in the postprandial state after breakfast, but not in the fasted state, decreased glucose excursions | [122] | |
Aerobic and eccentric exercise | Reduced all the indices of GV | [123] | |
Immediate post-breakfast physical activity | Improved mean, CV and AUC glucose | [124] |
GV, glycemic variability; CGM, continuous glucose monitoring; CV, coefficient of variation; GLP-1 RA, glucagon-like peptide 1 receptor agonist; PPG, postprandial glucose; MAGE, mean amplitude of glycemic excursions; TIR, time in range; AUC, area under the curve